摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5,6-二氢-4H-吡咯并[1,2-B]吡唑-2-羧酸 | 796729-03-8

中文名称
5,6-二氢-4H-吡咯并[1,2-B]吡唑-2-羧酸
中文别名
5,6-二氢-4H-吡咯并[1,2-b]吡唑-2-羧酸
英文名称
5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2-carboxylic acid
英文别名
——
5,6-二氢-4H-吡咯并[1,2-B]吡唑-2-羧酸化学式
CAS
796729-03-8
化学式
C7H8N2O2
mdl
——
分子量
152.153
InChiKey
CSOYACNIOQHFQZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    381.6±30.0 °C(Predicted)
  • 密度:
    1.55
  • 溶解度:
    可溶于DMSO(少许)、甲醇(少许)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    55.1
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:3c6a5394fca1e0ddd2aff5fa633e517b
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 5,6-Dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxylic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 5,6-Dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxylic acid
CAS number: 796729-03-8

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H8N2O2
Molecular weight: 152.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5,6-二氢-4H-吡咯并[1,2-B]吡唑-2-羧酸叠氮磷酸二苯酯三乙胺 作用下, 以 叔丁醇 为溶剂, 反应 5.0h, 以15.5%的产率得到tert-butyl (5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)carbamate
    参考文献:
    名称:
    8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS
    摘要:
    提供了公式II的8-氟邻菲啉-1(2H)-酮化合物,其中X1、X2和X3中的一个或两个是N,包括立体异构体、互变异构体和其药用可接受盐,用于抑制Btk激酶,并用于治疗由Btk激酶介导的炎症等免疫紊乱。公开了使用公式II化合物进行哺乳动物细胞中的体外、体内和体内诊断以及治疗这类疾病或相关病理条件的方法。
    公开号:
    US20130116246A1
  • 作为产物:
    描述:
    5,6-二氢-4H-吡咯并[1,2-b]吡唑-2-羧酸乙酯 、 sodium hydroxide 作用下, 反应 3.0h, 以65%的产率得到5,6-二氢-4H-吡咯并[1,2-B]吡唑-2-羧酸
    参考文献:
    名称:
    黏着斑激酶抑制剂及其用途
    摘要:
    本发明属于药物领域,涉及一种黏着斑激酶抑制剂及其用途。具体的,本发明涉及一种新的黏着斑激酶抑制剂化合物,或其立体异构体、几何异构体、互变异构体、氮氧化物、水合物、溶剂化物、代谢产物、药学上可接受的盐或前药。本发明还涉及所述化合物和其药物组合物作为药物的用途,尤其是在制备用于治疗或预防癌症、肺动脉高压、病理性血管生成相关疾病的药物中的用途。
    公开号:
    CN108948019B
点击查看最新优质反应信息

文献信息

  • [EN] PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES<br/>[FR] DÉRIVÉS DE PHÉNOXYPYRIDINYLAMIDE ET LEUR UTILISATION DANS LE TRAITEMENT D'ÉTATS PATHOLOGIQUES INDUITS PAR LA PHOSPHODIÉSTERASE 4 (PDE4)
    申请人:ASTRAZENECA AB
    公开号:WO2009144494A1
    公开(公告)日:2009-12-03
    The present invention provides a compound of a formula (I), wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE4 mediated disease state.
    本发明提供了一种化合物的公式(I),其中变量在此定义;以及制备这种化合物的方法;以及在治疗PDE4介导的疾病状态中使用这种化合物。
  • [EN] MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS MACROCYCLIQUES POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
    申请人:PFIZER
    公开号:WO2013132376A1
    公开(公告)日:2013-09-12
    The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
    该发明涉及本文进一步定义的Φ式化合物及其药用盐,包括含有这些化合物和盐的药物组合物,以及它们的用途。本发明的化合物和盐抑制间变性淋巴瘤激酶(ALK)和/或EML4-ALK,并且适用于治疗或改善异常细胞增殖性疾病,如癌症。
  • [EN] TLR7/8 ANTAGONISTS AND USES THEREOF<br/>[FR] ANTAGONISTES DE TLR7/8 ET LEURS UTILISATIONS
    申请人:MERCK PATENT GMBH
    公开号:WO2018031434A1
    公开(公告)日:2018-02-15
    The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.
    本发明涉及式I化合物及其药用可接受的组合物,用作TLR7/8拮抗剂。
  • [EN] BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY<br/>[FR] COMPOSÉS BIARYLIQUES UTILES POUR LE TRAITEMENT DE MALADIES HUMAINES EN ONCOLOGIE, NEUROLOGIE ET IMMUNOLOGIE
    申请人:BIOGEN IDEC INC
    公开号:WO2015089337A1
    公开(公告)日:2015-06-18
    The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    本发明提供了作为布鲁顿酪氨酸激酶抑制剂并具有相同理想特性的化合物及其组合物。
  • [EN] PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6<br/>[FR] CARBOXAMIDES HÉTÉROAROMATIQUES SUBSTITUÉS PAR PIPÉRIDINYLE ET PIPÉRAZINYLE EN TANT QUE MODULATEURS DE GPR6
    申请人:TAKEDA PHARMACEUTICALS CO
    公开号:WO2018183145A1
    公开(公告)日:2018-10-04
    Disclosed are compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein L, R4, R5, R8, R10, R11, X1, X2, X3, X9, X12, and Z are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with GPR6.
    本公开涉及公式1的化合物及其药用可接受的盐,其中L、R4、R5、R8、R10、R11、X1、X2、X3、X9、X12和Z在规范中定义。本公开还涉及制备公式1化合物的材料和方法,包含它们的药物组合物,以及它们用于治疗与GPR6相关的疾病、紊乱和症状的用途。
查看更多

同类化合物

奥格列汀 吡唑并[3,4-a]吡咯里嗪 叔丁基3'-氨基-1',4'-二氢-5'H-螺[环丁烷-1,6'-吡咯并[3,4-C]吡唑]-5'-羧酸酯 5-苄基-1,4,5,6-四氢吡咯并[3,4-c]吡唑-3-羧酸乙酯 5-甲基-1H,4H,5H,6H-吡咯并[3,4-C]吡唑 5-叔丁基3-乙基4,6-二氢吡咯并[3,4-c]吡唑-3,5(1h)-二羧酸 5-叔丁基1-乙基3-氨基-3A,4,6,6A-四氢吡咯并[3,4-C]吡唑-1,5-二甲酯 5-BOC-3-氨基-4,6-二氢吡咯并[3,4-C]吡唑-1-甲酸乙酯 5,6-二氢-4H-吡咯并[1,2-b]吡唑-2-羧酸乙酯 5,6-二氢-4H-吡咯并[1,2-b]吡唑 5,6-二氢-4H-吡咯并[1,2-B]吡唑-3-羧酸 5,6-二氢-4H-吡咯并[1,2-B]吡唑-2-羧酸 5,6-二氢-3-羟基-4H-吡咯并[1,2-c][1,2,3]恶二唑-7-鎓内盐 4a,6c-二氮杂环丁[a]环戊二烯并[Cd]并环戊二烯 4,6-二氢吡咯并[3,4-C]吡唑-3,5(1H)-二甲酸5-叔丁酯 4,6-二氢-1H-吡咯[3,4-C]吡唑-5-甲酸丁酯 3-甲基-1,4,5,6-四氢-吡咯并[3,4-c]吡唑 3-溴-5,6-二氢-4H-吡咯并[1,2-b]吡唑 3-氨基-6-乙基-4,6-二氢吡咯并[3,4-C]吡唑-5(1H)-羧酸叔丁酯 3-氨基-6,6-二甲基-4,6-二氢吡咯并[3,4-C]吡唑-5(2H)-羧酸叔丁酯 3-氨基-6,6-二甲基- 吡咯并[3,4-c]吡唑-2,5(4H,6H)-二羧酸 5-(1,1-二甲基乙基) 2-乙酯 3-氨基-5-叔丁氧羰基-吡咯并[3,4-C]吡唑 3-氨基-4,6-二氢吡咯并[3,4-C]吡唑-5-甲酸叔丁酯 3-氨基-4,6-二氢-6,6-二甲基-吡咯并[3,4-c]吡唑-1,5-二甲酸 5-叔丁基 1-乙基酯 3-(4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷-2-基)-5,6-二氢-4H-吡咯并(1,2-B)吡唑 2-甲基-2-丙基3'-氨基-1',4'-二氢-5'H-螺[环丙烷-1,6'-吡咯并[3,4-c]吡唑]-5'-羧酸酯 2-(甲基磺酰基)-2,6-二氢吡咯并[3,4-c]吡唑-5(4H)-羧酸叔丁酯 2,4,5,6-四氢-2-(甲基磺酰基)-吡咯并[3,4-c]吡唑 2,3-二氮杂三环[5.2.1.02,6]癸-1(9),3,5,7-四烯 1-甲基-1,4,5,6-四氢吡咯并[3,4-c]吡唑盐酸盐 1-(4-四氢吡喃基)-1,4,5,6-四氢吡咯并[3,4-C]吡唑盐酸盐 1-(3-氨基-2,6-二氢吡咯并[3,4-c]吡唑-5(4H)-基)乙酮 1,4,5,6-四氢吡咯并[3,4-c]吡唑-3-胺 1,4,5,6-四氢吡咯并[3,4-C]吡唑 1,4,5,6-四氢吡咯并-[3,4-c]-吡唑双盐酸盐 1,4,5,6-四氢-1-甲基吡咯并[3,4-C]吡唑 (S)-3-氨基-N-(2-(二甲基氨基)-1-苯基乙基)-6,6-二甲基-4,6-二氢吡咯并[3 (9CI)-2,4,5,6-四氢-2-甲基-吡咯并[3,4-c]吡唑 5-(5-chloro-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(4-chlorophenyl)-2-cyclopropyl-3-(trifluoromethyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one 5-isopropylaminocarbonyl-3-phenyl-1-polystyrenenethylaminocarbonyl-4,6-dihydropyrrolo[3,4-c]pyrazole 5-(6-{[(3,4-cis)-3-fluoropiperidin-4-yl]oxy}-5-methylpyrimidin-4-yl)-1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole 4-(4-chloro-2-fluorophenyl)-5-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-1-ethyl-3-methyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one 4-(4-chloro-2-fluorophenyl)-5-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-2-ethyl-3-methyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one 5,5-dimethyl-2-(6-methylpyridin-2-yl)-3-(pyridine-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 5,5-dimethyl-2-(pyridin-2-yl)-3-(pyridin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 3-bromo-5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 1-cyano-2,3,7-triazabicyclo[3.3.0]oct-2-ene 3-(aminomethyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid 1,1-dimethylethyl ester 5-(5-chloro-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(4-chlorophenyl)-1,3-dimethyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one 4-(4-chlorophenyl)-5-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-3-hydroxy-2-methyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one